National Key R&D Program of China(2020YFA0710700,2022YFA1206000 and 2021YFA1201200);National Natural Science Foundation of China(82272844,81974459,82073796,81627901 and 82202860);Program for HUST Academic Frontier Youth Team(2018QYTD01);Open Funds of State Key Laboratory of Oncology in South China(HN2022-07).
Immune checkpoint blockade(ICB)therapy,particularly antibodies targeting the programmed death receptor 1(PD-1)and its ligand(PD-L1),has revolutionized cancer treatment.However,its efficacy as a standalone therapy rema...